Indeed, we found that anti-TREM2 used in combination with neoAg SLP vax (initiated on day 12 post-transplant) enhanced efficacy in Y1.7LI tumor-bearing mice (Figure 7D). This evidence concerns the gene TREM2 and neoplasm.